Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads

Hepatology Research

Volumn 41, Issue 2, 2011, Pages 126-132

  Itoh, Yoshito ^a   Nishimura, Takeshi ^a   Hashimoto, Hiroaki ^a   Yamaguchi, Kanji ^a   Niimi, Toshihisa ^a   Yokomizo, Chihiro ^a   Fujii, Hideki ^a   Minami, Masahito ^a   Yasui, Kohichiroh ^a   Mitsuyoshi, Hironori ^a   Okanoue, Takeshi ^b   Takehara, Tetsuo ^c   Hiasa, Yoichi ^d   Onji, Morikazu ^d   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Genotype 1b; Peginterferon and ribavirin combination therapy; Predictive formula

Indexed keywords

AMINO ACID; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACCURACY; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79251484687     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00750.x     Document Type: Article

References (21)

1. Manns MP, McHutchinson JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
2. Fried MW, Schiffman ML, Reddy KR etal. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50years in Japan. Intervirology 2010; 53: 39-43.
4. Izumi N, Nishiguchi S, Hino K etal. Management of hepatitis C: Consensus of Japan Society of Hepatology. Hepatol Res 2010; 40: 347-68.
5. Iwasaki Y, Ikeda H, Araki Y etal. Limitations of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
6. Shirakawa H, Matsumoto A, Joshita S etal. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60.
7. Saito H, Ebinuma H, Ojiro K etal. On-treatment predictions of success in peginterferon/ribavirin treatment using a novel formula. World J Gastroenterol 2010; 16: 89-97.
8. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response in interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
9. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1a: amino acid substitutions in the core region and low-density lipoprotein cholesterol level. J Hepatol 2007; 46: 403-10.
10. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5 A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
11. Kato N, Hijikata M, Ootsuyama Y etal. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87: 9524-8.
12. Izumi N, Nishiguchi S, Hino K etal. Management of Hepatitis C: Consensus of Japan Society of Hepatology 2010. Hepatol Res 2010; 40: 347-68.
13. Iino S, Okita K, Omata M etal. Clinical efficacy of PEG-Interferon alfa-2b and ribavirin combination therapy for 48weeks in chronic hepatitis C patients with genotype 1 and high viral load -retrospective comparison with Interferon alfa-2b and ribavirin combination therapy for 24weeks. Kantansui 2004; 49: 1099-121.
14. Yamada G, Iino S, Okuno T etal. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon- alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008; 28: 9-16.
15. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predict hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
16. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-11-9.
17. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
18. Berg T, von Wagner M, Nasser S etal. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus72weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
19. Sanchez-Tapies JM, Diago M, Escartin P etal. Peginterferon-alfa2a plus ribavirin for 48 versus 72weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
20. Pearlman BL, Ehleben C, Saifee S etal. Treatment extension to 72weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46: 1688-94.
21. Ide T, Hino T, Ogata K etal. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009; 104: 70-5.